γ-Acetylenic-GABA

γ-Acetylenic GABA^[1]
Names
	IUPAC name 4-Aminohex-5-ynoic acid
	Other names Γ-Acetylenic-GABA; 4-Amino-5-hexynoic acid;
Identifiers
CAS Number	57659-38-8 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL330129;
ChemSpider	3334;
ECHA InfoCard	100.165.059
EC Number	637-345-7;
PubChem CID	3452;
UNII	PG9G3XCD6P;
CompTox Dashboard (EPA)	DTXSID40973249 ;
	InChI InChI=1S/C6H9NO2/c1-2-5(7)3-4-6(8)9/h1,5H,3-4,7H2,(H,8,9) Key: BJNIHWSOVCDBHS-UHFFFAOYSA-N;
	SMILES C#CC(CCC(=O)O)N;
Properties
Chemical formula	C6H9NO2
Molar mass	127.143 g·mol−1
Hazards
	GHS labelling:
Pictograms
Signal word	Warning
Hazard statements	H315, H319, H335
Precautionary statements	P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, P501
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

γ-Acetylenic GABA, also known as 4-aminohex-5-ynoic acid is a potent and irreversible inhibitor of GABA-T.^[3]

Mechanism of action

Like other GABA-T inhibitors, γ-acetylenic GABA causes GABA levels in the brain to be elevated. This is due to 4-aminobutyrate transaminase being the enzyme that converts γ-aminobutyric acid to L-glutamate. Inhibiting the enzyme stops this conversion from happening.

Potential uses

Anti convulsant

Continuous administration of γ-acetylenic GABA on rats during four days was able to reduce or completely stop seizures that were induced by amygdala overstimulation.^[4]

Treatment of tardive dyskinesia

A study has showed that γ-acetylenic GABA could reduce tardive dyskinesia symptoms. This result mostly happened in subjects receiving higher doses.^[5]

References

^ https://pubchem.ncbi.nlm.nih.gov/compound/4-Aminohex-5-ynoic-acid
^ "4-Aminohex-5-ynoic acid". pubchem.ncbi.nlm.nih.gov.
^ Tell, Guy; Böhlen, Peter; Schechter, Paul J.; Koch-Weser, Jan; Agid, Yves; Bonnet, A. M.; Coquillat, Gilles; Chazot, Guy; Fischer, Catherine (February 1981). "Treatment of Huntington disease with γ ‐acetylenic GABA, an irreversible inhibitor of GABA‐ transaminase: Increased CSF GABA and homocarnosine without clinical amelioration". Neurology. 31 (2): 207. doi:10.1212/WNL.31.2.207. ISSN 0028-3878.
^ Myslobodsky, M. S.; Valenstein, E. S. (April 1980). "Amygdaloid kindling and the GABA system". Epilepsia. 21 (2): 163–175. doi:10.1111/j.1528-1157.1980.tb04058.x. hdl:2027.42/66112. ISSN 0013-9580. PMID 7358042.
^ Casey, Daniel E.; Gerlach, Jes; Magelund, Gerhard; Christensen, Torben Rosted (1980-12-01). "γ-Acetylenic GABA in Tardive Dyskinesia". Archives of General Psychiatry. 37 (12): 1376–1379. doi:10.1001/archpsyc.1980.01780250062007. ISSN 0003-990X.

[1] ttps://pubchem.ncbi.nlm.nih.gov/compound/4-Aminohex-5-ynoic-acid

[2] "4-Aminohex-5-ynoic acid". pubchem.ncbi.nlm.nih.gov.

[3] Tell, Guy; Böhlen, Peter; Schechter, Paul J.; Koch-Weser, Jan; Agid, Yves; Bonnet, A. M.; Coquillat, Gilles; Chazot, Guy; Fischer, Catherine (February 1981). "Treatment of Huntington disease with γ ‐acetylenic GABA, an irreversible inhibitor of GABA‐ transaminase: Increased CSF GABA and homocarnosine without clinical amelioration". Neurology. 31 (2): 207. doi:10.1212/WNL.31.2.207. ISSN 0028-3878.

[4] Myslobodsky, M. S.; Valenstein, E. S. (April 1980). "Amygdaloid kindling and the GABA system". Epilepsia. 21 (2): 163–175. doi:10.1111/j.1528-1157.1980.tb04058.x. hdl:2027.42/66112. ISSN 0013-9580. PMID 7358042.

[5] Casey, Daniel E.; Gerlach, Jes; Magelund, Gerhard; Christensen, Torben Rosted (1980-12-01). "γ-Acetylenic GABA in Tardive Dyskinesia". Archives of General Psychiatry. 37 (12): 1376–1379. doi:10.1001/archpsyc.1980.01780250062007. ISSN 0003-990X.

[1]

[2]

[3]

[4]

[5]